Three-Dimensional Dose Model for the Comparison of 177Lu-HuCC49ΔCH2 and 177Lu-HuCC49 Radioimunotherapy in Mice Bearing Intraperitoneal Xenografts
- 1 April 2003
- journal article
- research article
- Published by Mary Ann Liebert Inc in Cancer Biotherapy & Radiopharmaceuticals
- Vol. 18 (2) , 239-247
- https://doi.org/10.1089/108497803765036418
Abstract
Uptake and dose distributions in peritoneal LS174T colon tumor xenografts were compared for a humanized construct of the CC49 (HuCC49) high-affinity anti-TAG-72 monoclonal antibody and a construct with the CH2 region deleted (HuCC49ΔCH2), both labeled with 177Lu using a PA-DOTA bifunctional chelating agent and injected in the peritoneum. Tumors were resected and serially sectioned at 1 h, 4 h, 24 h, and 48 h postinjection. Between 5 and 24 (average 16) sections were retained per tumor for autoradiography. The typical section interval was 340 μm and thickness was 16 μm. Tumor sections were air dried and placed on film and/or phosphor screen. Section images were digitized at 100 μm resolution electronically (phosphor screen) or by laser densitometer (film). Section images were used to generate tumor surface descriptions and activity distributions by reconstructing the activity densities in three dimensions. Three-dimensional dose-rate calculations, performed using a point kernel for 177Lu, were used to prepare radial histograms describing the variation in dose rate as a function of distance from the tumor center to surface. At early times postinjection, the 177Lu-HuCC49ΔCH2 antibody displayed higher dose rates near the tumor surface compared to the 177Lu-HuCC49 antibody. At 24 h postinjection, dose rate distributions appeared similar for both antibodies and more uniform than at earlier times. The 177Lu-HuCC49ΔCH2 antibody indicated improved uniformity at 48 h postinjection. Cell survival calculations based on the three-dimensional dose rate distributions favored 177Lu-HuCC49ΔCH2 for equal injection activities. However the most significant effect was the greater injected dose tolerated for the 177Lu-HuCC49ΔCH2 antibody based on equivalent estimated bone marrow dose.Keywords
This publication has 8 references indexed in Scilit:
- Improved synthesis of the bifunctional chelating agent 1,4,7,10-tetraaza-N-(1-carboxy-3-(4-nitrophenyl)propyl)-N′,N″,N‴-tris(acetic acid)cyclododecane (PA-DOTA)Bioorganic & Medicinal Chemistry, 1999
- Dosimetric comparison of bolus and continuous injections of CC49 monoclonal antibody in a colon cancer xenograft modelCancer, 1997
- PHASE II TRIAL OF 131I-CC49 Mab PLUS ALPHA INTERFERON (rIFNα) IN BREAST CANCERJournal of Immunotherapy, 1994
- Three-dimensional reconstruction of monoclonal antibody uptake in tumor and calculation of beta dose-rate nonuniformityCancer, 1994
- Application of the linear-quadratic model with incomplete repair to radionuclide directed therapyThe British Journal of Radiology, 1991
- Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.Proceedings of the National Academy of Sciences, 1989
- Macroscopic dosimetry for radioimmunotherapy: Nonuniform activity distributions in solid tumorsMedical Physics, 1989
- Radioimmunotherapy of athymic mice bearing human colon carcinomas with monoclonal antibody B72.3: Histological and autoradiographic study of effects on tumors and normal organsEuropean Journal of Cancer and Clinical Oncology, 1987